Clinical-Virology Core

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 4U54CA260517-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020.0
    2025.0
  • Known Financial Commitments (USD)

    $486,601
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    . Kari Nadeau
  • Research Location

    United States of America
  • Lead Research Institution

    STANFORD UNIVERSITY
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

CLINICAL AND VIROLOGY CORE: SUMMARY The Clinical and Virology Core (CVC) of the U54 will continue and expand recruitment of clinical cohorts of COVID-19 patients with increased proportions of populations at risk for severe disease and medically underserved. The CVC will provide state-of-the-art biospecimen support for Projects 1- 3 and clinical and assay data to the Administrative/Data Analysis Core. The CVC will also oversee personnel and procedures to implement and manage the clinical cohorts, and serve as the hub from which all Projects will obtain high-quality deidentified clinical and virologic data, and optimally preserved patient specimens from each patient. In addition, the CVC will be a focus of new immunological and virology assay development, with the goal (and established track record) of rapid translation to implementation in CLIA-regulated Clinical Laboratories.